IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boyle

Serial No.:

09/211,297

Filed:

December 14, 1998

For:

Osteoprotegerin Binding Proteins A

Docket No.: A-451F

Group Art Unit No.: 1652

Examiner: Not yet known

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, Applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form. In accordance with Rule §1.98(d), copies of the patents, publications or other information listed in the information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application U.S. Serial No. 08/880,855, filed June 23, 1997, which is relied upon for the earlier filing date under 35 U.S.C.§120.

This information disclosure statement is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicants presently cite references DE, DF and DG which were cited in the prosecution of co-pending U.S. Serial No. 09/079,088, filed May 14, 1998.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen, Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Robert B. Winter

Attorney/Agent for Applicant(s) 34,458

Registration No.:

Phone: (805) 447-2425 Date: MARCH 24, 1999

Please send all future correspondence to:

U.S. Patent Operations/ RBW

M/S 27-4-A

AMGEN INC.

One Amgen Center Drive

Thousand Oaks, California 91320-1789

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant

Commissioner for Patents, Washington, D.C. 20231, on the date appearing below